These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34681945)

  • 1. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
    Ramaswamy M; Tummala R; Streicher K; Nogueira da Costa A; Brohawn PZ
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease.
    Tanaka Y; Kusuda M; Yamaguchi Y
    Mod Rheumatol; 2023 Aug; 33(5):857-867. PubMed ID: 36440704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferon as a target of treatment in SLE.
    Lee PY; Reeves WH
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):323-30. PubMed ID: 17214578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon lambda in inflammation and autoimmune rheumatic diseases.
    Goel RR; Kotenko SV; Kaplan MJ
    Nat Rev Rheumatol; 2021 Jun; 17(6):349-362. PubMed ID: 33907323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches.
    Lazar S; Kahlenberg JM
    Annu Rev Med; 2023 Jan; 74():339-352. PubMed ID: 35804480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.
    Kim JM; Park SH; Kim HY; Kwok SK
    Int J Mol Sci; 2015 Jun; 16(6):14158-70. PubMed ID: 26110387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).
    Mathian A; Felten R; Alarcon-Riquelme ME; Psarras A; Mertz P; Chasset F; Vital EM; Arnaud L
    Joint Bone Spine; 2024 Mar; 91(2):105627. PubMed ID: 37640261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferons in Systemic Lupus Erythematosus.
    Sirobhushanam S; Lazar S; Kahlenberg JM
    Rheum Dis Clin North Am; 2021 Aug; 47(3):297-315. PubMed ID: 34215365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological actions of anifrolumab (Saphnelo
    Ueha T; Kusuda M; Shibata S; Hirata M; Ozaki N
    Nihon Yakurigaku Zasshi; 2022; 157(4):271-279. PubMed ID: 35781459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing cGAS-STING axis for therapeutic benefits in systemic lupus erythematosus.
    Chang L
    Int J Rheum Dis; 2024 Jul; 27(7):e15256. PubMed ID: 38982864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets.
    Crow MK
    Ann Rheum Dis; 2023 Aug; 82(8):999-1014. PubMed ID: 36792346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferon signature in systemic lupus erythematosus.
    Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
    Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the biology of type I interferons.
    Kalliolias GD; Ivashkiv LB
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S1. PubMed ID: 20392288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus.
    Gatto M; Depascale R; Stefanski AL; Schrezenmeier E; Dörner T
    Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101864. PubMed ID: 37625930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anifrolumab: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1795-1802. PubMed ID: 34554438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.